Table 2.
Best overall tumor response and median overall survival in elderly patients and the total study population
| Patient population | ||||||
|---|---|---|---|---|---|---|
| Age ≥65 yr | Age ≥70 yr | All patients | ||||
| Everolimus plus BSC (n = 112) |
Placebo plus BSC (n = 41) |
Everolimus plus BSC (n = 53) |
Placebo plus BSC (n = 20) |
Everolimus plus BSC (n = 277) |
Placebo plus BSC (n = 139) |
|
| Best overall tumor response, n (%) | ||||||
| CR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| PR | 3 (2.7) | 0 (0.0) | 2 (3.8) | 0 (0.0) | 5 (1.8) | 0 (0.0) |
| SD | 77 (68.8) | 18 (43.9) | 38 (71.7) | 7 (35.0) | 185 (66.8) | 45 (32.4) |
| PD | 21 (18.8) | 18 (43.9) | 8 (15.1) | 11 (55.0) | 57 (20.6) | 74 (53.2) |
| Unknown | 11 (9.8) | 5 (12.2) | 5 (9.4) | 2 (10.0) | 30 (10.8) | 20 (14.4) |
| ORR | 3 (2.7) | 0 (0.0) | 2 (3.8) | 0 (0.0) | 5 (1.8) | 0 (0.0) |
| Overall survival, mo, median (95% CI) | 14.78 (11.96–20.27) | 16.13 (8.48–22.93) | 13.57 (9.82–21.82) | 13.63 (5.09–22.93) | 13.57 (11.96–17.87) | 13.01 (10.09–16.66) |
| HR (95% CI) | 1.07 (0.69–1.67) | 0.85 (0.47–1.55) | 0.9 (0.71–1.14) | |||
| p value | 0.381 | 0.301 | 0.183 | |||
BSC = best supportive care; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; ORR = overall response rate; ORR = CR plus PR; CI = confidence interval; HR = hazard ratio.